Journal of Cancer Biology

Streptococcus pyogenes infection continues to be a worldwide public health problem causing various diseases in humans, including impetigo and oropharyngeal infections that are responsible for the development of rheumatic fever (RF), a multi-organ inflammatory disorder, Rheumatic heart disease (RHD) is its major sequel that leads to heart valves lesions, clinically classified as regurgitation and/or stenosis.

The promising results of immune checkpoint inhibitors (ICIs) in tumors have changed the current treatment modality for cancer. ICIs response prediction is urgently needed for the personalized therapy approach. In the recent issue of the Journal of Oncology, Zixin Hu et al. proposed that DNA methylation alternations contribute to tumor microenvironment (TME) reshapement to predict the ICIs response. Notwithstanding the global DNA methylation loss, the repression of T cell receptor signaling and the fellow costimulators by DNA hypermethylation contributed to the cold TME and ICIs resistance.

Multicentric reticulohistiocytosis (MRH) is a rare granulomatous disease manifesting by the subsequent appearance of erosive aggressive polyarthritis and typical skin papulonodular lesions. It can also affect internal organs such as the lungs, hearts in addition to rare cases of mesenteric lymphadenopathy and urogenital lesions.

Living cell could be considered the most sophisticated anti-entropy machinery born in the heart of the strong and ferocious pro-entropy environment of the primordial ocean full of boiling and salty water, some thirty-eight hundred million years ago on this planet. Evolution of prokaryotes with a simple cell membrane to eukaryotes and later on multi-cellular organisms, has necessitated the birth and evolution of a protective microenvironment, which could shield and secure evolution of living organisms by its sophisticated anti-entropy components

The advent of immune checkpoint inhibitors (ICI) targeting CTLA-4 and PD-1/PD-L1 pathways has revolutionized cancer treatment with significantly improved outcomes across a spectrum of cancers [1,2]. Although ICI therapy offers significant clinical benefits, these treatments can also lead to various immune-related adverse events (irAEs) that may negatively impact patient outcomes. Although the precise mechanism of irAE is not fully understood, they demonstrate many clinical features similar to autoimmune diseases. IRAEs are thought to result from bystander effects of activated T-cells, cross-reactivity between tumor and host tissues, and the role of the gut microbiome in immune activation [3].